CSL annual R&D day overview
![](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--72a5fdcb8549c0252d373a251befaa725e13a1bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lKYW5CbFp3WTZCa1ZVT2hOeVpYTnBlbVZmZEc5ZlptbHNiRnNIYVFISWFRSEkiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a788536266c8d052a67a95e113f2ebbff3ad0a97/34555966e256f39eefafa6eb2f711a721425616712.png)
Morgans
CSL hosted its annual R&D day yesterday. Overall, we came away with a better appreciation of the company’s protein therapeutics technical platform, underpinned by a core focus on plasma fractionation and recombinant technology across four key verticals (ie Immunoglobulins (43% of total sales), Specially Products (17% of total sales), Haemophilia (19% of total sales) and novel Breakthrough Medicines), and the R&D pipeline’s competitiveness, helping to support our 3 year earnings CAGR of c10% (cons c9%). We continue to view the name as a core portfolio holding and make no changes to our forecast or pricing at this time. While FY16 is a reinvestment year where underlying earnings growth slows, we remain confident in the future growth trajectory as it is underpinned by a strong blood fraction business (5-7% mkt growth), ongoing strength in Speciality products (12%+ growth) and at least five new products slated to launch over the next 12 months (CSL, Add, Price Target A$103.75)
1 topic
1 stock mentioned
![Scott Power](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--72a5fdcb8549c0252d373a251befaa725e13a1bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lKYW5CbFp3WTZCa1ZVT2hOeVpYTnBlbVZmZEc5ZlptbHNiRnNIYVFISWFRSEkiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a788536266c8d052a67a95e113f2ebbff3ad0a97/34555966e256f39eefafa6eb2f711a721425616712.png)
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
![Scott Power](https://assets.livewiremarkets.com/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZ3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--72a5fdcb8549c0252d373a251befaa725e13a1bb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lKYW5CbFp3WTZCa1ZVT2hOeVpYTnBlbVZmZEc5ZlptbHNiRnNIYVFISWFRSEkiLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a788536266c8d052a67a95e113f2ebbff3ad0a97/34555966e256f39eefafa6eb2f711a721425616712.png)
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise